IPO
Financing will support continued clinical development of gene therapies and surgical delivery systems for retinal diseases
Achilles Therapeutics announces it has closed a £100 million Series B financing led by incoming U.S. investor RA Capital Management, corner-stoned by founding investor Syncona and joined by important new investors including Forbion, Invus, Perceptive Advisors and Redmile Group.
Santhera Pharmaceuticals reports first half-year results as of June 30, 2019, and provides an update on its pipeline and strategic focus.
Benelux’ largest biotech investor Aat van Herk commits a €20 million investment in diagnostics company SkylineDx after reaching major milestones in 2018, financing SkylineDx’ market potential of over $1 billion annually based on their current progress in the melanoma field.
A fully integrated biopharmaceutical company - Uni-Bio Science Group Limited are pleased to announce that its interim results for the period ended 30 June 2019
Esperion announced that, on August 27, 2019, the Compensation Committee of Esperion’s Board of Directors granted non-qualified stock options to purchase an aggregate of 39,500 shares of its common stock and 35,388 restricted stock units to eighteen new colleagues under Esperion’s 2017 Inducement Equity Incentive Plan.
MGB Biopharma announces the completion of its latest funding round.
Ergomed plc will announce its interim results for the six months ending 30 June 2019 on 25September 2019.
Vivoryon Therapeutics AG announced its financial results for the first six months of 2019 ending June 30.
MyoKardia, Inc., announced its participation in the following upcoming investor conferences:
PRESS RELEASES